The economic impact of parallel imports of pharmaceuticals

Original title: Effekten af parallelimporteret medicin

Parallel import of pharmaceuticals has taken place in Denmark and the rest of the EU since the 1970s. In 2018, parallel imports accounted for 14% of turnover in the Danish market for medicinal products. Parallel-imported pharmaceuticals are original pharmaceuticals imported from another EU/EEA country where they are cheaper than in Denmark. Hence, they are the same medicinal products as the ones the original manufacturers sell in Denmark.

The main conclusions of our study are:

The study is commissioned by the Danish Association of Parallel Importers of Pharmaceuticals (Foreningen for Parallelimportører af Medicin).

Download the report in English


Related work

Swedish Association of the Pharmaceutical Industry (Läkemedelsindustriföreningen) The value of clinical trials in Sweden
The Danish Radiographer Society (Radiograf Rådet) RT-radiographers’ role in the healthcare sector
The Danish Diabetes Association (Diabetesforeningen) Economic impact of sensor-based glucose monitoring of diabetes in Denmark
Ministry of Employment and Economic Affairs of Finland Making markets work in the interest of patients
The Suppliers of Parallel Imported Medicines in Finland Savings from parallel import of pharmaceuticals in Finland 2016-2020